Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally. The company offers AdimFlu-S, a quadrivalent influenza vaccine; suspensions for injection influenza vaccines; and tetanus toxoid alum precipitated product for the prevention of tetanus after injury. It also develops AdimrSC-2f, a subunit protein-based vaccine for the prevention of COVID-19; H5N1 vaccine; and cell culture-derived Japanese encephalitis vaccine. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. and changed its name to Adimmune Corporation in 2001. Adimmune Corporation was incorporated in 1965 and is headquartered in Taichung, Taiwan.
Frequently asked questions
What sector does Adimmune Corp (4142) operate in?
Adimmune Corp belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Adimmune Corp (4142) current stock price?
As of the latest data, Adimmune Corp stock price is NT$18.20, with a previous close of NT$18.10. Adimmune Corp gained NT$0.10 in the last trading session, representing a 0.55% increase.
What is Adimmune Corp (4142) current market capitalization?
Adimmune Corp market cap is approximately 7.67 billion.
What is Adimmune Corp (4142) Earnings Per Share (EPS)?
The trailing EPS is -NT$0.34, and the forward EPS is NT$0.12.
What is Adimmune Corp (4142) EBITDA?
Adimmune Corp EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -120.17 million.
Does Adimmune Corp (4142) pay dividends?
No. Adimmune Corp does not pay a dividend.
What is Adimmune Corp (4142) beta (volatility) score?
Adimmune Corp has a beta of 0.266, indicating lower volatility than the overall market.
